A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies.

Goff LW, Rothenberg ML, Lockhart AC, Roth BJ, VerMeulen WL, Chan E, Berlin JD
Am J Clin Oncol. 2008 31 (5): 413-6

PMID: 18838875 · DOI:10.1097/COC.0b013e318168ef2a

OBJECTIVES - This phase I study was conducted to evaluate the combination of irinotecan, a topoisomerase I inhibitor, with epirubicin, a topoisomerase II inhibitor, when administered sequentially on a once-every-three week basis.

METHODS - Irinotecan was administered at doses ranging from 100 to 150 mg/m(2) intravenously over 90 minutes, 24 hours before epirubicin, in doses from 30 to 60 mg/m(2), every 3 weeks. Toxicity assessments were performed weekly. Tumor evaluation by radiographic and physical examination was performed after every 3 cycles using Response Evaluation Criteria in Solid Tumors.

RESULTS - Eighteen patients with metastatic solid tumors were enrolled in this study. The maximum tolerated dose and recommended phase II dose was irinotecan 150 mg/m(2) and epirubicin 30 mg/m(2). Dose-limiting toxicities were primarily neutropenia. Other toxicities at this dose level were mild. Three patients with colon cancer, 1 patient with renal cell cancer and 1 patient with adenosquamous cell carcinoma of the ethmoid sinus had stable disease. No objective responses were observed.

CONCLUSIONS - The maximum tolerated dose and recommended phase II dose for irinotecan and epirubicin administered 24 hours apart every 3 weeks was 150 mg/m(2) and 30 mg/m(2), respectively. Higher doses were limited by significant hematologic toxicity and fatigue.

MeSH Terms (15)

Aged Antineoplastic Combined Chemotherapy Protocols Camptothecin Disease-Free Survival Epirubicin Female Humans Irinotecan Male Maximum Tolerated Dose Middle Aged Neoplasms Salvage Therapy Survival Rate Treatment Outcome

Connections (3)

This publication is referenced by other Labnodes entities: